Kojo Elenitoba-Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kojo Elenitoba-Johnson has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Allyne Manzo
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications - Christopher M. Sande
Department of Laboratories, Seattle Children's Hospital and Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
2 shared publications - Jeninne Wright
Department of Pathology and Lab Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publications Lorraine Corsale
Department of Pathology and Lab Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publications- Matthew G. Hanna
Department of Pathology, UPMC Magee Womens Hospital, University of Pittsburgh, Pittsburgh, Pennsylvania
2 shared publications - Meera Hameed
Department of Pathology Memorial Sloan Kettering Cancer Center New York NY USA
2 shared publications
Latest Publications
- 8 January 2026
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (3) , 192-197
Quantitative reverse transcription PCR coupled with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1
Aims: The diagnosis and therapeutic decision-making in chronic myeloid leukaemia (CML) depend on the detection and quantification of BCR::ABL1 . Currently, no clinical assay is used in routine practice to simultaneously quantify multiple BCR::ABL1 isoforms, requiring separate tests for each isoform. To address this challenge, we have developed and optimised an assay (BloodHound) that leverages quantitative reverse transcription PCR (RT-qPCR) and high-resolution melting (HRM) technologies to simultaneously detect and quantify four BCR::ABL1 isoforms (p190, p210, p230 and p203), with a limit of detection of 0.001%. Methods: To evaluate the clinical utility of this assay, we analysed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML. Sanger sequencing was used as an orthogonal method to confirm fusion junction identity, and the Qiagen ipsogen BCR::ABL1 RT-qPCR assay was used for quantitative comparison. Results: BCR::ABL1 was detected in 20.9% of samples, with p210 alone being the most prevalent (86.1% (161/187), 95 CI 80.3% to 90.7%), followed by coexpression of p190 and p210 (12.3% (23/187), 95% CI 7.6% to 17.0%), while p190 alone (1.1% (2/187), 95% CI 0.1% to 3.8%) and p230 alone (0.5% (1/187), 95% CI 0% to 2.9%) were rare and p203 was not detected. The assay demonstrated high sensitivity and specificity, with 100% concordance with Sanger sequencing and showed excellent agreement with the Qiagen BCR::ABL1 RT-qPCR assay (r=0.998). Conclusions: The present multiplex RT-qPCR/HRM assay may help streamline clinical workflows, enhance diagnostic precision and offer a practical platform for studying CML clonal dynamics. It also holds promise for facilitating interlaboratory standardisation of non-p210 quantification.
- 8 January 2026
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (3) , 192-197
Quantitative reverse transcription PCR coupled with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1
Aims: The diagnosis and therapeutic decision-making in chronic myeloid leukaemia (CML) depend on the detection and quantification of BCR::ABL1 . Currently, no clinical assay is used in routine practice to simultaneously quantify multiple BCR::ABL1 isoforms, requiring separate tests for each isoform. To address this challenge, we have developed and optimised an assay (BloodHound) that leverages quantitative reverse transcription PCR (RT-qPCR) and high-resolution melting (HRM) technologies to simultaneously detect and quantify four BCR::ABL1 isoforms (p190, p210, p230 and p203), with a limit of detection of 0.001%. Methods: To evaluate the clinical utility of this assay, we analysed 895 peripheral blood and bone marrow samples from patients with suspected, established or relapsed CML. Sanger sequencing was used as an orthogonal method to confirm fusion junction identity, and the Qiagen ipsogen BCR::ABL1 RT-qPCR assay was used for quantitative comparison. Results: BCR::ABL1 was detected in 20.9% of samples, with p210 alone being the most prevalent (86.1% (161/187), 95 CI 80.3% to 90.7%), followed by coexpression of p190 and p210 (12.3% (23/187), 95% CI 7.6% to 17.0%), while p190 alone (1.1% (2/187), 95% CI 0.1% to 3.8%) and p230 alone (0.5% (1/187), 95% CI 0% to 2.9%) were rare and p203 was not detected. The assay demonstrated high sensitivity and specificity, with 100% concordance with Sanger sequencing and showed excellent agreement with the Qiagen BCR::ABL1 RT-qPCR assay (r=0.998). Conclusions: The present multiplex RT-qPCR/HRM assay may help streamline clinical workflows, enhance diagnostic precision and offer a practical platform for studying CML clonal dynamics. It also holds promise for facilitating interlaboratory standardisation of non-p210 quantification.
- Open Access
- 1 September 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 103 (11) , 100246
Quality Management System in Clinical Digital Pathology Operations at a Tertiary Cancer Center
- 1 September 2023
- Published by Elsevier in Laboratory Investigation
- Vol. 103 (11) , 100246
Open AccessQuality Management System in Clinical Digital Pathology Operations at a Tertiary Cancer Center
- Open Access
- 17 May 2023
- Published by Elsevier in Journal of Pathology Informatics
- Vol. 14, 100318
Digital pathology operations at a tertiary cancer center: Infrastructure requirements and operational cost
- 17 May 2023
- Published by Elsevier in Journal of Pathology Informatics
- Vol. 14, 100318
Open AccessDigital pathology operations at a tertiary cancer center: Infrastructure requirements and operational cost
- Open Access
- 8 May 2023
- Published by BMJ in Journal of Clinical Pathology
- Vol. 77 (9) , 639-644
High-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants
Aims: Identification of recurrent genetic alterations in JAK2, MPL and CALR remains crucial in the diagnosis of Philadelphia-negative myeloproliferative neoplasms (MPNs). Current laboratory testing algorithms may entail batching and/or sequential testing, involving multiple testing modalities and sometimes send-out testing that increase the technical and economic demands on laboratories while delaying patient diagnoses. To address this gap, an assay based on PCR and high-resolution melting (HRM) analysis was developed for simultaneous evaluation of JAK2 exons 12–14, MPL exon 10 and CALR exon 9, embodied in the HemeScreen® (hereafter ‘HemeScreen’) MPN assay. Methods: The HemeScreen MPN assay was validated with blood and bone marrow samples from 982 patients with clinical suspicion for MPN. The HRM assay and Sanger sequencing were performed in independent Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories with Sanger sequencing (supported by droplet digital PCR) serving as the gold standard. Results: HRM and Sanger sequencing had an overall concordance of 99.4% with HRM detecting 133/139 (96%) variants confirmed by sequencing (9/10 MPL, 25/25 CALR, 99/104 JAK2), including 114 single nucleotide variants and 25 indels (3–52 bp). Variants consisted of disease-associated (DA) variants (89%), variants of unclear significance (2%) and non-DA variants (9%) with a positive predictive value of 92.3% and negative predictive value of 99.5%. Conclusions: These studies demonstrate the exquisite accuracy, sensitivity and specificity of the HRM-based HemeScreen MPN assay, which serves as a powerful, clinically applicable platform for rapid, simultaneous detection of clinically relevant, somatic disease variants.
- 8 May 2023
- Published by BMJ in Journal of Clinical Pathology
- Vol. 77 (9) , 639-644
Open AccessHigh-resolution melting assay for rapid, simultaneous detection of JAK2, MPL and CALR variants
Aims: Identification of recurrent genetic alterations in JAK2, MPL and CALR remains crucial in the diagnosis of Philadelphia-negative myeloproliferative neoplasms (MPNs). Current laboratory testing algorithms may entail batching and/or sequential testing, involving multiple testing modalities and sometimes send-out testing that increase the technical and economic demands on laboratories while delaying patient diagnoses. To address this gap, an assay based on PCR and high-resolution melting (HRM) analysis was developed for simultaneous evaluation of JAK2 exons 12–14, MPL exon 10 and CALR exon 9, embodied in the HemeScreen® (hereafter ‘HemeScreen’) MPN assay. Methods: The HemeScreen MPN assay was validated with blood and bone marrow samples from 982 patients with clinical suspicion for MPN. The HRM assay and Sanger sequencing were performed in independent Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories with Sanger sequencing (supported by droplet digital PCR) serving as the gold standard. Results: HRM and Sanger sequencing had an overall concordance of 99.4% with HRM detecting 133/139 (96%) variants confirmed by sequencing (9/10 MPL, 25/25 CALR, 99/104 JAK2), including 114 single nucleotide variants and 25 indels (3–52 bp). Variants consisted of disease-associated (DA) variants (89%), variants of unclear significance (2%) and non-DA variants (9%) with a positive predictive value of 92.3% and negative predictive value of 99.5%. Conclusions: These studies demonstrate the exquisite accuracy, sensitivity and specificity of the HRM-based HemeScreen MPN assay, which serves as a powerful, clinically applicable platform for rapid, simultaneous detection of clinically relevant, somatic disease variants.
- 8 December 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (2) , 87-93
Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms
- 8 December 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (2) , 87-93
Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms